Imbalance of APOB Lipoproteins and Large HDL in Type 1 Diabetes Drives Atherosclerosis.

atherosclerosis cardiovascular diseases cholesterol hypertension transcytosis

Journal

Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103

Informations de publication

Date de publication:
03 Jun 2024
Historique:
medline: 3 6 2024
pubmed: 3 6 2024
entrez: 3 6 2024
Statut: aheadofprint

Résumé

Individuals with type 1 diabetes (T1D) generally have normal or even higher HDL (high-density lipoprotein)-cholesterol levels than people without diabetes yet are at increased risk for atherosclerotic cardiovascular disease (CVD). Human HDL is a complex mixture of particles that can vary in cholesterol content by >2-fold. To investigate if specific HDL subspecies contribute to the increased atherosclerosis associated with T1D, we created mouse models of T1D that exhibit human-like HDL subspecies. We also measured HDL subspecies and their association with incident CVD in a cohort of people with T1D. We generated LDL receptor-deficient ( Diabetic Our results suggest that the balance between APOB lipoproteins and the larger HDL subspecies contributes to atherosclerosis progression and incident CVD in the setting of T1D and that larger HDLs exert atheroprotective effects on endothelial cells rather than by promoting macrophage cholesterol efflux.

Sections du résumé

BACKGROUND UNASSIGNED
Individuals with type 1 diabetes (T1D) generally have normal or even higher HDL (high-density lipoprotein)-cholesterol levels than people without diabetes yet are at increased risk for atherosclerotic cardiovascular disease (CVD). Human HDL is a complex mixture of particles that can vary in cholesterol content by >2-fold. To investigate if specific HDL subspecies contribute to the increased atherosclerosis associated with T1D, we created mouse models of T1D that exhibit human-like HDL subspecies. We also measured HDL subspecies and their association with incident CVD in a cohort of people with T1D.
METHODS UNASSIGNED
We generated LDL receptor-deficient (
RESULTS UNASSIGNED
Diabetic
CONCLUSIONS UNASSIGNED
Our results suggest that the balance between APOB lipoproteins and the larger HDL subspecies contributes to atherosclerosis progression and incident CVD in the setting of T1D and that larger HDLs exert atheroprotective effects on endothelial cells rather than by promoting macrophage cholesterol efflux.

Identifiants

pubmed: 38828596
doi: 10.1161/CIRCRESAHA.123.323100
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Vishal Kothari (V)

Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, UW Medicine Diabetes Institute (V.K., Y.H., F.K., M.S.-A., J.E.K., B.S., J.W.H., T.V., K.E.B.).

Tse W W Ho (TWW)

Keenan Centre for Biomedical Research, St. Michael's Hospital, Toronto, Canada (T.W.W.H., W.L.L.).
Department of Laboratory Medicine and Pathobiology (T.W.W.H., W.L.L.).

Ainara G Cabodevilla (AG)

Division of Endocrinology, Diabetes and Metabolism (A.G.C., I.J.G.).

Yi He (Y)

Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, UW Medicine Diabetes Institute (V.K., Y.H., F.K., M.S.-A., J.E.K., B.S., J.W.H., T.V., K.E.B.).

Farah Kramer (F)

Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, UW Medicine Diabetes Institute (V.K., Y.H., F.K., M.S.-A., J.E.K., B.S., J.W.H., T.V., K.E.B.).

Masami Shimizu-Albergine (M)

Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, UW Medicine Diabetes Institute (V.K., Y.H., F.K., M.S.-A., J.E.K., B.S., J.W.H., T.V., K.E.B.).

Jenny E Kanter (JE)

Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, UW Medicine Diabetes Institute (V.K., Y.H., F.K., M.S.-A., J.E.K., B.S., J.W.H., T.V., K.E.B.).

Janet Snell-Bergeon (J)

Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora (J.S.-B.).

Edward A Fisher (EA)

Division of Cardiology, Department of Medicine, New York University Grossman School of Medicine (E.A.F.).

Baohai Shao (B)

Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, UW Medicine Diabetes Institute (V.K., Y.H., F.K., M.S.-A., J.E.K., B.S., J.W.H., T.V., K.E.B.).

Jay W Heinecke (JW)

Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, UW Medicine Diabetes Institute (V.K., Y.H., F.K., M.S.-A., J.E.K., B.S., J.W.H., T.V., K.E.B.).

Jacob O Wobbrock (JO)

The Information School (J.O.W.).

Warren L Lee (WL)

Keenan Centre for Biomedical Research, St. Michael's Hospital, Toronto, Canada (T.W.W.H., W.L.L.).
Department of Laboratory Medicine and Pathobiology (T.W.W.H., W.L.L.).
Interdepartmental Division of Critical Care and the Department of Biochemistry, University of Toronto, Canada (W.L.L.).

Ira J Goldberg (IJ)

Division of Endocrinology, Diabetes and Metabolism (A.G.C., I.J.G.).

Tomas Vaisar (T)

Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, UW Medicine Diabetes Institute (V.K., Y.H., F.K., M.S.-A., J.E.K., B.S., J.W.H., T.V., K.E.B.).

Karin E Bornfeldt (KE)

Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, UW Medicine Diabetes Institute (V.K., Y.H., F.K., M.S.-A., J.E.K., B.S., J.W.H., T.V., K.E.B.).
Department of Laboratory Medicine and Pathology, University of Washington, Seattle (K.E.B.).

Classifications MeSH